Year: 2026
Type: article
Abstract: Three-prime repair exonuclease 1 (TREX1) is a 3’→5’ exonuclease that degrades cytoplasmic DNA to prevent aberrant activation of innate immune responses. During tumorigenesis, TREX1 expression is frequently dysregulated in a cancer type-specific manner, leading to suppression of the cGAS-STING signaling pathway and reduced type I interferon (IFN-I) production, thereby facilitating tumor immune evasion in certain tumor contexts. Additionally, altered TREX1 expression is associated with chromosomal instability and cancer stem cell characteristics, promoting tumor invasion and metastasis in a context-dependent manner. Pharmacological inhibition or genetic deletion of TREX1 significantly enhances the efficacy of immune checkpoint inhibitors and STING agonists in preclinical models, indicating its potential as an immunotherapeutic target.Some inhibitors have shown selective inhibition potential against TREX1 in preclinical studies, but the selectivity for TREX2 still requires further validation. Moreover, TREX1-deficient tumor cells can serve as autologous cancer vaccines by promoting immunogenic cell death and enhancing CD8+ T cell and NK cell activation in preclinical models. This review systematically summarizes the molecular mechanisms of TREX1 in tumorigenesis and immune escape, discusses the pharmacological strategies for TREX1 targeting, and evaluates the therapeutic potential and challenges of TREX1-based immunotherapy, providing a theoretical foundation for clinical translation.
Source: Frontiers in Immunology
Authors: Yuan-Yuan Wu, Wei-Lan Li, Hua Shao, Lingli Huang
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: TREX1, cancer immunotherapy, tumor immune evasion, cGAS-STING pathway, type I interferon, cytosolic DNA sensing, chromosomal instability, cancer stem cells, metastasis, immune checkpoint inhibitors, STING agonist, TREX2, immunogenic cell death, cancer vaccines, CD8+ T cells, natural killer cells
Open Access status: gold
Estimated APC paid: $3,801
Funder: Jiangsu Cancer Hospital
OpenAlex ID: W7234623864
